Michelangelo Bauwelz Gonzatti , José Edvar Monteiro Júnior , Antônio José Rocha , Jonathas Sales de Oliveira , Antônio José de Jesus Evangelista , Fátima Morgana Pio Fonseca , Vânia Marilande Ceccatto , Ariclécio Cunha de Oliveira , José Ednésio da Cruz Freire
{"title":"Mechanism of molecular interaction of sitagliptin with human DPP4 enzyme - New Insights","authors":"Michelangelo Bauwelz Gonzatti , José Edvar Monteiro Júnior , Antônio José Rocha , Jonathas Sales de Oliveira , Antônio José de Jesus Evangelista , Fátima Morgana Pio Fonseca , Vânia Marilande Ceccatto , Ariclécio Cunha de Oliveira , José Ednésio da Cruz Freire","doi":"10.1016/j.advms.2023.10.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p><span>Dipeptidyl peptidase 4 (DPP</span><sub>4</sub>) inactivates a range of bioactive peptides. The cleavage of insulinotropic peptides and glucagon-like peptide 1 (GLP<sub>1</sub>) by DPP<sub>4</sub><span> directly influences glucose homeostasis<span>. This study aimed to describe the mode of interaction between sitagliptin (an antidiabetic drug) and human DPP</span></span><sub>4</sub> using <span><em>in silico</em></span> approaches.</p></div><div><h3>Materials and methods</h3><p><span>Docking studies were conducted using AutoDock Vina, 2D and 3D schematic drawings were obtained using PoseView and PLIP servers, and the DPP</span><sub>4</sub>-sitagliptin complex was visualized with Pymol software.</p></div><div><h3>Results</h3><p>The best affinity energy to form the DPP<sub>4</sub>-sitagliptin complex was <em>E</em>-value = - 8.1 kcal mol<sup>−1</sup><span>, as indicated by docking simulations. This result suggests a strong interaction. According to our observations, hydrophobic interactions involving the amino acids residues Tyr</span><sup>663</sup> and Val<sup>712</sup><span>, hydrogen bonds (Glu</span><sup>203</sup>, Glu<sup>204</sup>, Tyr<sup>663</sup>, and Tyr<sup>667</sup>), π-Stacking interactions (Phe<sup>355</sup> and Tyr<sup>667</sup>), and halogenic bonds (Arg<sup>123</sup>, Glu<sup>204</sup>, and Arg<sup>356</sup>) were prevalent in the DPP<sub>4</sub>-sitagliptin complex. Root Mean Square Deviation prediction also demonstrated that the global structure of the human DPP<sub>4</sub> did not have a significant change in its topology, even after the formation of the DPP<sub>4</sub>-sitagliptin complex.</p></div><div><h3>Conclusion</h3><p>The stable interaction between the sitagliptin ligand and the DPP<sub>4</sub><span><span> enzyme was demonstrated through </span>molecular docking simulations. The findings presented in this work enhance the understanding of the physicochemical properties of the sitagliptin interaction site, supporting the design of more efficient gliptin-like iDPP</span><sub>4</sub> inhibitors.</p></div>","PeriodicalId":7347,"journal":{"name":"Advances in medical sciences","volume":"68 2","pages":"Pages 402-408"},"PeriodicalIF":2.5000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in medical sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1896112623000421","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose
Dipeptidyl peptidase 4 (DPP4) inactivates a range of bioactive peptides. The cleavage of insulinotropic peptides and glucagon-like peptide 1 (GLP1) by DPP4 directly influences glucose homeostasis. This study aimed to describe the mode of interaction between sitagliptin (an antidiabetic drug) and human DPP4 using in silico approaches.
Materials and methods
Docking studies were conducted using AutoDock Vina, 2D and 3D schematic drawings were obtained using PoseView and PLIP servers, and the DPP4-sitagliptin complex was visualized with Pymol software.
Results
The best affinity energy to form the DPP4-sitagliptin complex was E-value = - 8.1 kcal mol−1, as indicated by docking simulations. This result suggests a strong interaction. According to our observations, hydrophobic interactions involving the amino acids residues Tyr663 and Val712, hydrogen bonds (Glu203, Glu204, Tyr663, and Tyr667), π-Stacking interactions (Phe355 and Tyr667), and halogenic bonds (Arg123, Glu204, and Arg356) were prevalent in the DPP4-sitagliptin complex. Root Mean Square Deviation prediction also demonstrated that the global structure of the human DPP4 did not have a significant change in its topology, even after the formation of the DPP4-sitagliptin complex.
Conclusion
The stable interaction between the sitagliptin ligand and the DPP4 enzyme was demonstrated through molecular docking simulations. The findings presented in this work enhance the understanding of the physicochemical properties of the sitagliptin interaction site, supporting the design of more efficient gliptin-like iDPP4 inhibitors.
期刊介绍:
Advances in Medical Sciences is an international, peer-reviewed journal that welcomes original research articles and reviews on current advances in life sciences, preclinical and clinical medicine, and related disciplines.
The Journal’s primary aim is to make every effort to contribute to progress in medical sciences. The strive is to bridge laboratory and clinical settings with cutting edge research findings and new developments.
Advances in Medical Sciences publishes articles which bring novel insights into diagnostic and molecular imaging, offering essential prior knowledge for diagnosis and treatment indispensable in all areas of medical sciences. It also publishes articles on pathological sciences giving foundation knowledge on the overall study of human diseases. Through its publications Advances in Medical Sciences also stresses the importance of pharmaceutical sciences as a rapidly and ever expanding area of research on drug design, development, action and evaluation contributing significantly to a variety of scientific disciplines.
The journal welcomes submissions from the following disciplines:
General and internal medicine,
Cancer research,
Genetics,
Endocrinology,
Gastroenterology,
Cardiology and Cardiovascular Medicine,
Immunology and Allergy,
Pathology and Forensic Medicine,
Cell and molecular Biology,
Haematology,
Biochemistry,
Clinical and Experimental Pathology.